2024年3月14日 · For patients with metastatic melanoma lacking a BRAF mutation, there have been important advances in systemic therapy, such as checkpoint inhibitor immunotherapy. …

BRAF testing is recommended for all patients with Stage III and IV melanoma. In addition, some Stage II melanoma patients, in the context of a clinical trial, should also undergo BRAF testing.

2023年5月23日 · In this review, we will discuss available and developing therapies for BRAF WT patients with metastatic melanoma, particularly focusing on molecular targeted options for …

Since the initial discovery that a subset of patients with cutaneous melanoma harbor BRAF mutations, substantial research has been focused on determining the pathologic …

2021年12月17日 · Results from a large study are expected to help determine the best treatment approach for some people with an advanced form of melanoma. The NCI-sponsored clinical …

This review delineates the current role of BRAF in melanoma progression and metastasis. It discusses targeted therapies and resistance mechanisms to BRAF inhibitors, and illustrates …

2024年2月8日 · We review the basics of genomic features of both BRAF mutant and BRAF wild-type melanoma as well as efforts underway to develop new targeted therapies involving the …

2023年8月14日 · For patients with BRAF wild-type, unresectable and/or metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): …

We review the basics of genomic features of both BRAF mutant and BRAF wild-type melanoma as well as efforts underway to develop new targeted therapies involving the mitogen-activated …

2020年11月20日 · Purpose: The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. …